Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs
Open Access
- 1 March 2017
- journal article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 6 (1) , 11
Abstract
Background: Radiogenetic therapy is a novel approach in the treatment of cancer, which employs genetic modification to alter the sensitivity of tumor cells to the effect of applied radiation.Aim: To select a potent radiation inducible promoter in the context of brain tumors and to investigate if CArG radio responsive motifs or other elements in the promoter nucleotide sequences can correlate to its response to radiation.Methods: To select initial candidates for promoter inducible elements, the levels of mRNA expression of six different promoters were assessed using Quantitative RTPCR in D54 MG cells before and after radiation exposure. Recombinant Ad/reporter genes driven by five different promoters; CMV, VEGF, FLT‐1, DR5 and survivin were constructed. Glioma cell lines were infected with different multiplicity of infection of the (promoter) Ad or CMV Ad. Cells were then exposed to a range of radiation (0–12 Gy) at single fraction. Fluorescent microscopy, Luc assay and X‐gal staining was used to detect the level of expression of related genes. Different glioma cell lines and normal astrocytes were infected with Ad survivin and exposed to radiation. The promoters were analyzed for presence of CArG radio‐responsive motifs and CCAAT box consensus using NCBI blast bioinformatics software.Results: Radiotherapy increases the expression of gene expression by 1.25–2.5 fold in different promoters other than survivin after 2 h of radiation. RNA analysis was done and has shown an increase in copy number of tenfold for survivin. Most importantly cells treated with RT and Ad Luc driven by survivin promoter showed a fivefold increase in expression after 2 Gy of radiation in comparison to non‐irradiated cells. Presence or absence of CArG motifs did not correlate with promoter response to radiation. Survivin with the best response to radiation had the lowest number of CCAAT box.Conclusion: Survivin is a selective potent radiation inducible promoter for glioblastoma viral gene therapy and this response to radiation could be independent of CArG motifs.Keywords
This publication has 67 references indexed in Scilit:
- Emerging insights into the molecular and cellular basis of glioblastomaGenes & Development, 2012
- Oncolytic Virus Therapy for Glioblastoma MultiformeThe Cancer Journal, 2012
- Cancer Stem Cells: The Final Frontier for Glioma VirotherapyStem Cell Reviews and Reports, 2010
- Virotherapy against malignant glioma stem cellsCancer Letters, 2009
- Gene- and Viral-Based Therapies for Brain TumorsNeurotherapeutics, 2009
- Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteinsJournal of Clinical Investigation, 2008
- Low-Dose Radiation Enhances Survivin-Mediated Virotherapy against Malignant Glioma Stem CellsCancer Research, 2008
- Targeting survivin in cancer therapy: fulfilled promises and open questionsCarcinogenesis, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma applicationCancer Gene Therapy, 2006